SecBot SecBot
SECBOTREPLAY Home › Report › CERT

CERT · Certara agreed to sell its regulatory and medical writing business to…

Certara, Inc. · 8-K filed Apr 22, 2026 at 07:00 ET

At the news

BULLISHIMPACT 7/10

8-K filed Apr 22, 2026 at 07:00 ET

Certara agreed to sell its regulatory and medical writing business to Veristat for up to $135 million in cash, consisting of $100 million upfront and up to $35 million in earn-outs. The move sharpens focus on its core Model-Informed Drug Development (MIDD) platform and is expected to close in Q2 2026.

  • Certara is selling its regulatory and medical writing business to Veristat
  • Total consideration is up to $135 million: $100 million upfront cash and $35 million in contingent earn-outs
  • The business generated $50 million in revenue and $17 million in adjusted EBITDA in 2025
  • Transaction expected to close in Q2 2026, subject to customary conditions

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access